Japan· JP-4900409X1022
イデカブタゲン ビクルユーセル
A medicinal product containing イデカブタゲン ビクルユーセル, registered in Japan by ブリストル・マイヤーズ スクイブ, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- イデカブタゲン ビクルユーセル
- Manufacturer
- ブリストル・マイヤーズ スクイブ
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
イデカブタゲン ビクルユーセル in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesAbecmaCelgene Corporation
- SwitzerlandAbecma Infusionsdispersion, von 260 bis 500 × 10e6 CAR-positiven lebensfähigen T-ZellenBristol-Myers Squibb SA
- CzechiaABECMABristol-Myers Squibb Pharma EEIG, Dublin
- SpainABECMA 260-500 x 10e6 CELULAS DISPERSION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandAbecmaBristol-Myers Squibb Pharma EEIG
- BelgiumAbecma 260-500 x 10*6 cellsBristol-Myers Squibb Pharma
- IrelandAbecma 260 - 500 x 106 cells dispersion for infusionBristol-Myers Squibb Pharmaceuticals uc
- IcelandAbecmaBristol-Myers Squibb Pharma EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Abecma
- Liechtenstein · Abecma
- Norway · Abecma
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b6775341-cc5d-4b3a-8f13-941de4cac76b GET /v1/drugs/b6775341-cc5d-4b3a-8f13-941de4cac76b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１患者当たり",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4900409X1022",
"category": "注射薬",
"price_yen": 32647761,
"generic_name": "イデカブタゲン ビクルユーセル",
"product_name_jp": null,
"therapeutic_class": "4900",
"transitional_expiry": null
}See everything about イデカブタゲン ビクルユーセル.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.